Cronos completes CanAdelaar deal before Cronos Group stock reports results
Published on 10/25/2026 at 02:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEuropean expansion and reporting calendar
- Cronos completed the CanAdelaar acquisition for EUR 57.5 million on October 15, 2026.
- Second-quarter revenue reached USD 53.01 million, while gross profit totaled USD 28.45 million.
- Cronos will discuss third-quarter 2026 results on November 5, 2026.
Cronos Group (ISIN CA22717L1013) completed its acquisition of CanAdelaar for a base price of EUR 57.5 million on October 15, 2026, expanding its European adult-use cannabis platform. The company said the transaction also includes cash earnout payments tied to CanAdelaar's normalized EBITDA in 2026 and 2027, according to Cronos Group.
CanAdelaar adds European scale
The acquisition gives Cronos a platform in the Netherlands' regulated adult-use cannabis pilot program. The company said the purchase price represented 1.4 times CanAdelaar's annualized first-half 2026 revenue and 2.9 times its annualized adjusted EBITDA, based on results for the six months ended June 30, 2026.
CanAdelaar generated annualized revenue of EUR 41.60 million and annualized adjusted EBITDA of EUR 20.10 million in that period. Its management team remains in place, while Cronos plans to use the business to support its borderless product strategy, according to MarketScreener.
What does the deal mean for growth?
The transaction follows a strong second quarter. Cronos reported USD 53.01 million of revenue for the second quarter of 2026, up 58.00 percent year over year, while gross profit reached USD 28.45 million and the gross profit margin was 54.00 percent. Adjusted EBITDA totaled USD 13.10 million, an improvement of USD 11.40 million from the second quarter of 2025, according to Benzinga.
Reporting dates and legal exposure
Cronos is scheduled to discuss its third-quarter 2026 results on November 5, 2026, at 8:30 a.m. Eastern Time, according to the company's investor-relations calendar. A separate court hearing on November 19, 2026, is scheduled to address a proposed USD 10.00 million settlement tied to historical securities claims, as reported by Simply Wall St.
Expansion meets the next earnings test
For investors, the next report will show whether the European acquisition is beginning to complement Cronos' existing growth engine. The second-quarter revenue increase of 58.00 percent and adjusted EBITDA improvement of USD 11.40 million provide the operating benchmark for the November update.
The further course of trading is shown by the continuously updated real-time quote of Cronos Group stock.
Cronos Group at a glance
- Company: Cronos Group Inc.
- ISIN: CA22717L1013
- Ticker: CRON
- Primary exchange: Nasdaq
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
- Next earnings date: November 5, 2026
Market context: Market report Nasdaq Composite.
